Boundless Bio, Inc.
General ticker "BOLD" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $27.3M (TTM average)
Boundless Bio, Inc. follows the US Stock Market performance with the rate: 39.4%.
Estimated limits based on current volatility of 2.5%: low 2.85$, high 2.99$
Factors to consider:
- Total employees count: 200000 as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Limited operating history, Operational and conduct risks, Clinical trial failure, Regulatory and compliance, Manufacturing risks
- Current price 24.9% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.81$, 2.27$]
- 2026-12-31 to 2027-12-31 estimated range: [0.79$, 2.19$]
Short-term BOLD quotes
Long-term BOLD plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $54.80MM | $73.27MM | $63.55MM |
| Operating Income | $-54.80MM | $-73.27MM | $-63.55MM |
| Non-Operating Income | $5.36MM | $7.90MM | $5.36MM |
| R&D Expense | $42.64MM | $55.27MM | $44.84MM |
| Income(Loss) | $-49.43MM | $-65.36MM | $-58.20MM |
| Net Income(Loss)* | $-49.43MM | $-65.36MM | $-58.20MM |
| Stockholders Equity | $-127.08MM | $150.64MM | $98.65MM |
| Assets | $129.89MM | $206.41MM | $157.06MM |
| Operating Cash Flow | $-46.85MM | $-60.84MM | $-46.66MM |
| Capital expenditure | $0.63MM | $2.54MM | $0.55MM |
| Investing Cash Flow | $-38.26MM | $-26.10MM | $37.80MM |
| Financing Cash Flow | $97.90MM | $89.82MM | $0.14MM |
| Earnings Per Share** | $-2.22 | $-3.85 | $-2.60 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.